TITLE

Progressive licensing needs progressive open debate

AUTHOR(S)
Hébert, Paul C.
PUB. DATE
June 2007
SOURCE
CMAJ: Canadian Medical Association Journal;6/19/2007, Vol. 176 Issue 13, p1801
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects on the need for close examination on the progressive licensing of drugs by regulatory agencies in Canada. The author comments that pharmaceutical products cannot be easily approved and cannot be driven by profit. He points out that regulatory agencies must focus on a transparent, patient-centered regulatory system which ensures drugs are safe and efficacious before and after their release.
ACCESSION #
25360225

 

Related Articles

  • Who would want to be an inspector? Marwaha, Gurminder // Pharmaceutical Technology Europe;Jun2007, Vol. 19 Issue 6, p8 

    The author reflects on the source of active pharmaceutical ingredients (API) being imported into the European Union (EU). He cites the hard responsibility of being a pharmaceutical inspector as to ensure the safety of the medicines when the call comes out to increase the number of inspections of...

  • London broker seeks support to create pharmaceutical mutual. Ladbury, Adrian // Business Insurance;12/18/2006, Vol. 40 Issue 51, p14 

    The article reports on the efforts of Neil Campbell, a partner with broker JLT Risk Solutions, to garner support for his idea of creating a mutual insurer could provide the answer to the liability coverage problems of global pharmaceutical companies. According to Campbell, a mutual insurer could...

  • Catching mice. Marwaha, Gurminder // Pharmaceutical Technology Europe;Oct2007, Vol. 19 Issue 10, p10 

    The author reflects on the pressures that the pharmaceutical industry faces. Among the mentioned pressures include consumers can easily sue the manufacturers, cheap drugs in the market coming from Asia and Eastern Europe and the ordinances from the regulatory authorities. He said that...

  • The Evolving Landscape for Pharmaceutical Product Liability Litigation in Canada. McKee, Gordon; Linley, Robin // Defense Counsel Journal;Jul2006, Vol. 73 Issue 3, p242 

    The article discusses the evolution of pharmaceutical product liability litigation in Canada. It includes developments in mass tort litigation in Canada, causes of action and remedies pursued by plaintiffs and the defenses asserted, and relevant aspects of Canadian procedure on trial practice....

  • German Product Liability Plaintiffs Make Progress with the Pharmaceutical Act and the Product Liability Act. Maurer, Anton G. // Defense Counsel Journal;Jul2006, Vol. 73 Issue 3, p275 

    The article explains the progress of the Pharmaceutical Act of 1976 and the Product Liability Act of 1989 in relation to product liability plaintiffs in Germany. Previous to these two laws, individuals who suffered injuries from pharmaceutical products are only protected by the tort law....

  • Manufacturers must share liability of unknown drug maker.  // Corporate Board;Mar/Apr90, Vol. 11 Issue 61, p27 

    Reports on the US Supreme Court's refusal to hear appeal made by various New York-based drug manufacturers on their share of liability for injuries or deaths caused by an unknown drugmaker. Prospects for shared liability for damages in various suits involving the use of the drug diethylstilbestrol.

  • Risk, reform & restatement. Wexler, Judith; Soni, Leena // Pharmaceutical Executive;Jul97, Vol. 17 Issue 7, p74 

    Examines the liability risks faced by pharmaceutical companies. Expanded worldwide product liability; Legal judgments and settlements in product liability lawsuits; Legal alternatives for pharmaceutical companies to avoid litigation from product liability. INSET: Basics of black letter law..

  • NTI legislation expected in 1998.  // Drug Store News;11/17/97, Vol. 19 Issue 19, pCP4 

    Reports on the Arizona pharmacy board's call for all pharmacists in the state to familiarize themselves with all the issues surrounding narrow therapeutic index (NTI) drugs. Expected introduction of a legislation that limits the right of pharmacists to substitute generics for NTI drugs.

  • Drug patents and promotion: a trade off for Europe? Taylor, David // BMJ: British Medical Journal (International Edition);7/20/91, Vol. 303 Issue 6795, p151 

    Focuses on the impact of the pharmaceutical patent regulation on the pharmaceutical industry in Europe. Desire of the industry for longer patent terms; Provisions of the regulation; Impact of the regulation on industry competition.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics